Table 4.

Proportion of trials deciding in favor of H₁ when including patients treated at the MTD, MTD −1, MTD +1 for the four scenarios of Table 3 and trials under Scheme 3. T₁ is based on model based efficacy rates; T₂ is based on an acceptable region of efficacy and toxicity and T₃ is based on the observed efficacy rate. Median Sample size and interquartile range (IQR) in order to make a decision in favor of H₁ at any dose.

	Test :	MTD−1	MTD	MTD+1	Median n (IQR)
Scenario 1
	T 1	0.06	0.20	0.56	35 ( 9, 201)
	T 2	0.18	0.26	0.49	34 (11, 201)
	T 3	0.03	0.17	0.52	60 (17, 201)
Scenario 2
	T 1	0.11	0.84	0.61	17 ( 7, 40)
	T 2	0.25	0.85	0.49	16 ( 8, 36)
	T 3	0.07	0.84	0.56	23 (12, 50)
Scenario 3
	T 1	0.07	0.53	0.60	24 ( 8, 71)
	T 2	0.19	0.58	0.54	21 ( 9, 58)
	T 3	0.04	0.50	0.57	33 (13, 89)
Scenario 4
	T 1	0.43	0.95	0.64	10 (5,21)
	T 2	0.53	0.96	0.62	11 (6,19)
	T 3	0.39	0.94	0.61	15 (9,27)